Tadbelt n wučči d isafaren
Tadbelt n wučči d isafaren (S Tegnizit: Food and Drug Administration - s usegzel: FDA neɣ USFDA) d tanegga yeṭṭafaren aɣlif n Iwunak Yeddukklen n Temrikt i yimeẓla n tdawsa d izerfan n wemdan. Akken i tga d yiwet gar tdeblin tiselkamin tifidiṛalyin deg Marikan.[1][2][3] Tadbelt n wučči d isafaren i d (tamasayt) ɣef taggaẓt d usnerni n tdawsa tamatut s ferru d waggal (asefqed) ɣef tɣellist n wučči d ifarisen n ubaɣa d tsutay d isafaren d yicraṭen d tnegwa tisnudranin d temhalin n tufkit n idammen d tinezririn
Asadaf n wučči d isafaren d tnezririnẒreg
Ẓeṛ daɣenẒreg
- ↑ Ridley DB, Grabowski HG, Moe JL (2006). "Developing drugs for developing countries". Health Aff (Millwood). 25 (2): 313–24. doi:10.1377/hlthaff.25.2.313. PMID 16522573. Unknown parameter
|akala n ufaylu=ignored (help); Unknown parameter|azmez n ufaylu=ignored (help) - ↑ MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Accessed October 9, 2007 Archived 2018-01-03 at the Wayback Machine
- ↑ Nelson, LS; Loh, M; Perrone, J (June 2014). "Assuring safety of inherently unsafe medications: the FDA risk evaluation and mitigation strategies". Journal of medical toxicology : official journal of the American College of Medical Toxicology. 10 (2): 165–72. doi:10.1007/s13181-013-0374-z. PMC 4057549. PMID 24414251.